Evofem Inc.   Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2009)

Organization Overview

First Clinical Trial
2011
NCT01306331
First Marketed Drug
2020
potassium bitartrate
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Evofem Inc. | EVOFEM INC

Active Ingredients

Marketed Drugs (3)

citric acid (2020)

lactic acid (2020)

potassium bitartrate (2020)

Drugs in Phase 3 Trials (7)

Key: Evofem Inc. (5) Acquired (2)

citric acid (2 trials)

evo100 (1 trial)

lactic acid (2 trials)

lipo-202 (5 trials)

nonoxynol-9 (Delfen) (1 trial)

potassium bitartrate (1 trial)

salmeterol (serevent) (8 trials)

Drugs in Phase 2 Trials (4)

Key: Evofem Inc. (1) Acquired (3)

fluticasone (cutivate) (6 trials)

isoprenaline (1 trial)

potassium hydrotartrate (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chlamydia Infections (Phase 3)

Gonorrhea (Phase 3)

Infections (Phase 2)

Sexually Transmitted Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 11